Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lifestyle-induced Hepatic Steatosis and Glucagon-stimulated Amino Acid Turnover
NCT04859322Completed
- Start
- Feb 2021
- Primary completion
- Dec 2021
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label trial of glucagon in non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus (T2DM). Primary endpoint: Nadir of total amino acid concentration. Started Feb 2021; status: completed.
02
Drugs
glucagon
03
Conditions
non-alcoholic fatty liver disease (NAFLD)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04859322.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04859322.